Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD 318.77
+1.33 (0.42%)
At close: Mar 9, 2026
Alnylam Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 1,657 | 966.43 | 812.69 | 866.39 | 819.98 | Upgrade
|
| Short-Term Investments | 1,251 | 1,728 | 1,627 | 1,326 | 1,616 | Upgrade
|
| Cash & Short-Term Investments | 2,908 | 2,695 | 2,439 | 2,192 | 2,436 | Upgrade
|
| Cash Growth | 7.94% | 10.46% | 11.27% | -9.98% | 29.94% | Upgrade
|
| Accounts Receivable | 777.57 | 405.31 | 327.79 | 237.96 | 198.57 | Upgrade
|
| Receivables | 777.57 | 405.31 | 327.79 | 237.96 | 198.57 | Upgrade
|
| Inventory | 82.72 | 78.51 | 89.15 | 128.96 | 86.36 | Upgrade
|
| Prepaid Expenses | 281.89 | 116.96 | 126.38 | 132.92 | 88.08 | Upgrade
|
| Total Current Assets | 4,051 | 3,295 | 2,983 | 2,692 | 2,809 | Upgrade
|
| Property, Plant & Equipment | 708.06 | 693.93 | 725.79 | 738.63 | 733.63 | Upgrade
|
| Long-Term Deferred Tax Assets | 125.98 | 116.86 | 10.1 | - | - | Upgrade
|
| Other Long-Term Assets | 81.63 | 133.9 | 111.29 | 115.48 | 101.1 | Upgrade
|
| Total Assets | 4,966 | 4,240 | 3,830 | 3,546 | 3,643 | Upgrade
|
| Accounts Payable | 115.72 | 88.42 | 55.52 | 98.09 | 73.43 | Upgrade
|
| Accrued Expenses | 821.34 | 701.38 | 654.73 | 513.78 | 372.33 | Upgrade
|
| Current Portion of Long-Term Debt | 220.07 | 113.02 | 54.99 | 40.29 | 37.08 | Upgrade
|
| Current Portion of Leases | 45.52 | 41.89 | 41.51 | 41.97 | 40.55 | Upgrade
|
| Current Unearned Revenue | 4.85 | 55.48 | 102.75 | 42.11 | 149.48 | Upgrade
|
| Other Current Liabilities | 258.86 | 186.09 | 58.28 | 31.68 | 22.84 | Upgrade
|
| Total Current Liabilities | 1,466 | 1,186 | 967.79 | 767.92 | 695.71 | Upgrade
|
| Long-Term Debt | 2,478 | 2,359 | 2,343 | 2,269 | 1,827 | Upgrade
|
| Long-Term Leases | 225.09 | 229.54 | 243.1 | 261.34 | 281.35 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 188.18 | 193.79 | 152.36 | Upgrade
|
| Other Long-Term Liabilities | 7.59 | 398.11 | 308.44 | 212.58 | 98.96 | Upgrade
|
| Total Liabilities | 4,177 | 4,173 | 4,051 | 3,705 | 3,055 | Upgrade
|
| Common Stock | 1.32 | 1.29 | 1.26 | 1.24 | 1.2 | Upgrade
|
| Additional Paid-In Capital | 7,510 | 7,388 | 6,811 | 6,455 | 6,058 | Upgrade
|
| Retained Earnings | -6,703 | -7,288 | -7,010 | -6,569 | -5,438 | Upgrade
|
| Comprehensive Income & Other | -20.1 | -34.52 | -23.38 | -44.65 | -33.26 | Upgrade
|
| Shareholders' Equity | 789.18 | 67.09 | -220.64 | -158.22 | 588.2 | Upgrade
|
| Total Liabilities & Equity | 4,966 | 4,240 | 3,830 | 3,546 | 3,643 | Upgrade
|
| Total Debt | 2,969 | 2,743 | 2,683 | 2,613 | 2,186 | Upgrade
|
| Net Cash (Debt) | -60.31 | -48.92 | -243.24 | -420.15 | 249.87 | Upgrade
|
| Net Cash Growth | - | - | - | - | -11.29% | Upgrade
|
| Net Cash Per Share | -0.45 | -0.38 | -1.95 | -3.45 | 2.11 | Upgrade
|
| Filing Date Shares Outstanding | 132.62 | 129.46 | 125.95 | 124.13 | 120.21 | Upgrade
|
| Total Common Shares Outstanding | 132.38 | 129.29 | 125.79 | 123.93 | 120.18 | Upgrade
|
| Working Capital | 2,584 | 2,109 | 2,015 | 1,924 | 2,113 | Upgrade
|
| Book Value Per Share | 5.96 | 0.52 | -1.75 | -1.28 | 4.89 | Upgrade
|
| Tangible Book Value | 789.18 | 67.09 | -220.64 | -158.22 | 588.2 | Upgrade
|
| Tangible Book Value Per Share | 5.96 | 0.52 | -1.75 | -1.28 | 4.89 | Upgrade
|
| Land | 9.08 | 9.08 | 9.08 | 9.08 | 9.08 | Upgrade
|
| Buildings | 297.62 | 294.51 | 271.65 | 269.32 | 262.64 | Upgrade
|
| Machinery | 247.12 | 225.2 | 202.89 | 173.1 | 137.86 | Upgrade
|
| Construction In Progress | 40.95 | 7.67 | 30.1 | 14.6 | 80.75 | Upgrade
|
| Leasehold Improvements | 241.08 | 236.69 | 235.41 | 230.85 | 152.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.